{"id":"tislelizumab-radiotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Radiation dermatitis (enhanced by combination)"}]},"_chembl":{"chemblId":"CHEMBL4297840","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tislelizumab binds to programmed death receptor-1 (PD-1) on T lymphocytes, preventing engagement with its ligands (PD-L1 and PD-L2) expressed on tumor and immune cells, thereby releasing the brake on anti-tumor immunity. When combined with radiotherapy, the immunotherapy synergizes with radiation-induced tumor cell death and immunogenic effects to amplify T-cell activation and improve overall anti-tumor efficacy.","oneSentence":"Tislelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, restoring anti-tumor immune responses, and is combined with radiotherapy to enhance local and systemic tumor control.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:12:51.185Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (in combination with radiotherapy)"},{"name":"Other solid tumors amenable to radiotherapy (investigational)"}]},"trialDetails":[{"nctId":"NCT06563245","phase":"PHASE2, PHASE3","title":"Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2024-09-25","conditions":"Classical Hodgkin Lymphoma, Child, Adolescent","enrollment":96},{"nctId":"NCT07469306","phase":"PHASE2","title":"Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-08-10","conditions":"Locally Advanced Rectal Cancer","enrollment":130},{"nctId":"NCT07463248","phase":"PHASE2","title":"PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Wang Xin","startDate":"2026-03-05","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":64},{"nctId":"NCT06647680","phase":"PHASE2","title":"Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2025-06-01","conditions":"Rectal Cancer Patients","enrollment":35},{"nctId":"NCT05526924","phase":"PHASE1","title":"Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-03-07","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma","enrollment":30},{"nctId":"NCT07450040","phase":"","title":"Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma","status":"ENROLLING_BY_INVITATION","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-09-12","conditions":"ORR, OS, PFS","enrollment":60},{"nctId":"NCT07039162","phase":"PHASE2","title":"Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Ming-Yu Lien","startDate":"2025-09-26","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer","enrollment":45},{"nctId":"NCT07425795","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2025-10-10","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":36},{"nctId":"NCT07408609","phase":"PHASE2","title":"Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2026-02-26","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":114},{"nctId":"NCT07402538","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-24","conditions":"Oral Cancer, Oropharyngeal Cancer","enrollment":184},{"nctId":"NCT07332247","phase":"PHASE2","title":"PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-03","conditions":"Nasopharangeal Cancer, Recurrent Nasopharynx Carcinoma","enrollment":94},{"nctId":"NCT07131319","phase":"PHASE2, PHASE3","title":"SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2025-04-21","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07373990","phase":"PHASE3","title":"Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-15","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer","enrollment":418},{"nctId":"NCT06764355","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-07-23","conditions":"ESCC, Total Neoadjuvant Treatment, Pathological Complete Response","enrollment":50},{"nctId":"NCT07363512","phase":"PHASE2","title":"Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-01-05","conditions":"HCC - Hepatocellular Carcinoma","enrollment":27},{"nctId":"NCT06468280","phase":"PHASE2","title":"Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-11-08","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":84},{"nctId":"NCT05366829","phase":"PHASE2","title":"Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-07-25","conditions":"Carcinoma, Hepatocellular, Liver Cell Carcinoma","enrollment":35},{"nctId":"NCT07339488","phase":"PHASE2","title":"Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chuangzhen Chen","startDate":"2025-11-01","conditions":"Borderline Resectable Carcinoma, Unresectable Cancer, Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":43},{"nctId":"NCT06312982","phase":"PHASE2, PHASE3","title":"A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-03-16","conditions":"Locally Advanced Rectal Carcinoma","enrollment":375},{"nctId":"NCT07328854","phase":"PHASE3","title":"40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-20","conditions":"Nasopharyngeal Carcinoma","enrollment":346},{"nctId":"NCT07050056","phase":"PHASE2","title":"Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC","status":"RECRUITING","sponsor":"Northern Jiangsu People's Hospital","startDate":"2025-08-01","conditions":"Resectable NSCLC","enrollment":20},{"nctId":"NCT07320105","phase":"PHASE4","title":"Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-01-15","conditions":"Non-Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT07317609","phase":"PHASE1","title":"Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-15","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT06877299","phase":"PHASE2","title":"Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2025-07-04","conditions":"Lung Cancer, Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06494189","phase":"PHASE1","title":"Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2024-07-31","conditions":"Head and Neck Cancer","enrollment":9},{"nctId":"NCT07040956","phase":"PHASE2","title":"A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-06-28","conditions":"Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy, Immunotherapy","enrollment":98},{"nctId":"NCT07297030","phase":"PHASE2","title":"SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-20","conditions":"Rectal Cancer","enrollment":37},{"nctId":"NCT07296705","phase":"PHASE2","title":"Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-10-25","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":25},{"nctId":"NCT06349837","phase":"PHASE1","title":"Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-04-18","conditions":"Solid Tumor","enrollment":24},{"nctId":"NCT07264647","phase":"PHASE2","title":"Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2025-03-27","conditions":"Stage III NSCLC","enrollment":30},{"nctId":"NCT06914011","phase":"PHASE3","title":"Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-01-06","conditions":"Esophageal Cancer","enrollment":172},{"nctId":"NCT04974047","phase":"PHASE2","title":"Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-08-17","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":70},{"nctId":"NCT07248696","phase":"NA","title":"Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2025-10-04","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":32},{"nctId":"NCT07243938","phase":"PHASE2","title":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-15","conditions":"Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC)","enrollment":70},{"nctId":"NCT07235319","phase":"PHASE3","title":"PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-20","conditions":"Nasopharangeal Cancer, Distant Metastasis","enrollment":260},{"nctId":"NCT06804850","phase":"PHASE2","title":"Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC","status":"WITHDRAWN","sponsor":"West China Hospital","startDate":"2025-01-20","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT07231575","phase":"PHASE2","title":"Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-10","conditions":"Neoadjuvant Immunotherapy, NSCLC, Chemo-free Therapy","enrollment":39},{"nctId":"NCT06139419","phase":"PHASE2","title":"The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-25","conditions":"Non-small Cell Lung Cancer","enrollment":114},{"nctId":"NCT07198217","phase":"PHASE2","title":"Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient","status":"RECRUITING","sponsor":"Zibo Municipal Hospital","startDate":"2021-05-25","conditions":"NSCLC, Tislelizumab, Chemotherapy","enrollment":20},{"nctId":"NCT07196540","phase":"PHASE2","title":"IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-26","conditions":"Digestive System Neoplasms","enrollment":78},{"nctId":"NCT06838208","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC","status":"RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-02-25","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","enrollment":56},{"nctId":"NCT06884670","phase":"PHASE2","title":"Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-03-18","conditions":"Rectal Cancer","enrollment":130},{"nctId":"NCT06509568","phase":"PHASE2","title":"Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":92},{"nctId":"NCT07145931","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-20","conditions":"Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy","enrollment":24},{"nctId":"NCT05515796","phase":"PHASE2","title":"Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2022-09-01","conditions":"Immunotherapy, Gastric Cancer, Rectal Cancer","enrollment":200},{"nctId":"NCT07132463","phase":"PHASE3","title":"Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-08","conditions":"Rectal Cancer","enrollment":154},{"nctId":"NCT06333769","phase":"PHASE2","title":"Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Fujian Cancer Hospital","startDate":"2024-07-12","conditions":"Mid-low Rectal Cancer","enrollment":38},{"nctId":"NCT07104604","phase":"PHASE1","title":"Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital of Shantou University Medical College","startDate":"2025-08-01","conditions":"Rectal Cancer","enrollment":59},{"nctId":"NCT06841172","phase":"PHASE3","title":"Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-07-21","conditions":"OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy","enrollment":132},{"nctId":"NCT07086456","phase":"PHASE2","title":"Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-20","conditions":"Surufatinib, Tislelizumab, Concurrent Chemoradiotherapy","enrollment":80},{"nctId":"NCT07085182","phase":"PHASE2","title":"Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study","status":"RECRUITING","sponsor":"Zibo Municipal Hospital","startDate":"2024-01-13","conditions":"NSCLC, Tislelizumab, Chemotherapy","enrollment":20},{"nctId":"NCT06734702","phase":"PHASE3","title":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy","enrollment":497},{"nctId":"NCT07080437","phase":"","title":"An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Three Gorges Hospital of Chongqing University","startDate":"2021-03-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":40},{"nctId":"NCT07046221","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Esophagus Cancer","enrollment":60},{"nctId":"NCT07070622","phase":"PHASE3","title":"Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-11-01","conditions":"Rectal Cancer","enrollment":186},{"nctId":"NCT07067268","phase":"PHASE2","title":"Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-09-14","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":76},{"nctId":"NCT06379087","phase":"PHASE2","title":"Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC","status":"RECRUITING","sponsor":"Ji Yongling","startDate":"2024-05-01","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04833257","phase":"PHASE2","title":"Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-04-14","conditions":"Nasopharyngeal Carcinoma","enrollment":63},{"nctId":"NCT06507371","phase":"PHASE3","title":"Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-07-29","conditions":"Rectal Cancer","enrollment":170},{"nctId":"NCT07035860","phase":"","title":"Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ji Yongling","startDate":"2025-06-16","conditions":"Carbon Ion Radiotheray","enrollment":34},{"nctId":"NCT07030140","phase":"PHASE2","title":"Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-07-01","conditions":"Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer","enrollment":38},{"nctId":"NCT06167785","phase":"PHASE2","title":"A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-06-04","conditions":"Large B-cell Lymphoma","enrollment":76},{"nctId":"NCT05319574","phase":"PHASE2","title":"SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-04-24","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":46},{"nctId":"NCT06009861","phase":"PHASE2","title":"Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University Hospital of Stomatology","startDate":"2023-06-27","conditions":"Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma","enrollment":110},{"nctId":"NCT06446726","phase":"PHASE2","title":"Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-06-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT07000617","phase":"PHASE2","title":"A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-03-21","conditions":"NK/T Cell Lymphoma","enrollment":57},{"nctId":"NCT06997913","phase":"","title":"Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk Resectable Extrahepatic Cholangiocarcinoma（AICRC）","status":"ENROLLING_BY_INVITATION","sponsor":"Hengchao Yu","startDate":"2025-03-15","conditions":"Lymph Node Metastasis, Neurovascular Invasion, Pathology Showed R1 Resection","enrollment":10},{"nctId":"NCT04821765","phase":"PHASE2","title":"Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-10-01","conditions":"Esophagus Cancer, Chemoradiotherapy, Oligometastatic Disease","enrollment":35},{"nctId":"NCT06598527","phase":"PHASE3","title":"Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study","status":"RECRUITING","sponsor":"Yang Hong","startDate":"2024-10-15","conditions":"Lung Cancer (NSCLC)","enrollment":360},{"nctId":"NCT05941481","phase":"PHASE2","title":"Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2023-06-10","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":21},{"nctId":"NCT06990178","phase":"NA","title":"Adaptive Neoadjuvant Therapy for Esophageal Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center","startDate":"2028-03-01","conditions":"Esophageal Carcinoma, Neoadjuvant Therapy","enrollment":43},{"nctId":"NCT06978829","phase":"PHASE2","title":"Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-03-01","conditions":"LA HNSCC","enrollment":42},{"nctId":"NCT06965829","phase":"PHASE2","title":"The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-07-01","conditions":"Esophageal Cancer Stage III","enrollment":40},{"nctId":"NCT06848465","phase":"PHASE1","title":"LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-02-28","conditions":"Colorectal Cancer, Liver Metastasis, LDRT","enrollment":9},{"nctId":"NCT06093061","phase":"PHASE2","title":"Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2024-07-03","conditions":"Nasopharyngeal Carcinoma","enrollment":69},{"nctId":"NCT06957938","phase":"PHASE3","title":"Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-04-28","conditions":"Laryngeal Carcinoma, Hypopharyngeal Carcinoma","enrollment":168},{"nctId":"NCT03957590","phase":"PHASE3","title":"A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-06-12","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":370},{"nctId":"NCT06673693","phase":"PHASE2","title":"Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-15","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC","enrollment":24},{"nctId":"NCT06908733","phase":"PHASE2","title":"Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2025-03-31","conditions":"Non-Small Cell Lung Cancer (Stage III)","enrollment":30},{"nctId":"NCT06056804","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-01-03","conditions":"Locally Advanced Rectal Cancer","enrollment":20},{"nctId":"NCT04866836","phase":"PHASE2","title":"A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors","status":"TERMINATED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-10-01","conditions":"Cholangiocarcinoma","enrollment":20},{"nctId":"NCT06258811","phase":"PHASE3","title":"Neoadjuvant Immunochemotherapy for LAOSCC","status":"RECRUITING","sponsor":"Lai-ping Zhong","startDate":"2024-02-20","conditions":"Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma","enrollment":134},{"nctId":"NCT06851819","phase":"PHASE2","title":"Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-03-01","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":64},{"nctId":"NCT06835179","phase":"PHASE2","title":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-02","conditions":"Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer","enrollment":28},{"nctId":"NCT05937438","phase":"PHASE1, PHASE2","title":"Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2023-09-01","conditions":"Esophageal Carcinoma","enrollment":70},{"nctId":"NCT06695013","phase":"PHASE2","title":"Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-11-20","conditions":"B-NHL, CART Therapy","enrollment":144},{"nctId":"NCT06781112","phase":"PHASE2","title":"A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Weiwei Zhang","startDate":"2025-01-20","conditions":"TPF, Immunotherapy, Nasopharyngeal Carcinoma","enrollment":35},{"nctId":"NCT05972655","phase":"PHASE2","title":"Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2023-08-02","conditions":"Low Rectal Cancer","enrollment":32},{"nctId":"NCT06725498","phase":"PHASE2","title":"Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2024-12-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT06708650","phase":"NA","title":"Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Guiping People's Hospital","startDate":"2025-01-01","conditions":"Hepatocellular Carcinoma, Radiotherapy, PD-1 Inhibitors","enrollment":50},{"nctId":"NCT05758116","phase":"PHASE2","title":"Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2022-07-07","conditions":"Non-small Cell Lung Cancer, Consolidation Immunotherapy, Radiotherapy or Sequential Chemoradiation","enrollment":20},{"nctId":"NCT05520619","phase":"PHASE2","title":"Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-09-15","conditions":"Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":114},{"nctId":"NCT05919030","phase":"PHASE3","title":"A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Renmin Hospital of Wuhan University","startDate":"2023-07-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":155},{"nctId":"NCT04866017","phase":"PHASE3","title":"A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"BeiGene","startDate":"2021-06-17","conditions":"Non Small Cell Lung Cancer","enrollment":63},{"nctId":"NCT05468242","phase":"PHASE2","title":"Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-01-01","conditions":"Stage III Non-small Cell Lung Cancer","enrollment":116},{"nctId":"NCT04952597","phase":"PHASE2","title":"Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-07-15","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":126},{"nctId":"NCT06646588","phase":"PHASE2","title":"Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-04-01","conditions":"Esophageal Neoplasms","enrollment":67},{"nctId":"NCT06573398","phase":"PHASE2","title":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09-01","conditions":"Carcinoma, Pancreatic Ductal","enrollment":20},{"nctId":"NCT05086627","phase":"PHASE2","title":"Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2021-09-01","conditions":"Locally Advanced Rectal Cancer","enrollment":118},{"nctId":"NCT06554028","phase":"PHASE2","title":"Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-08","conditions":"Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":89,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tislelizumab + radiotherapy","genericName":"Tislelizumab + radiotherapy","companyName":"First Affiliated Hospital Xi'an Jiaotong University","companyId":"first-affiliated-hospital-xi-an-jiaotong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tislelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, restoring anti-tumor immune responses, and is combined with radiotherapy to enhance local and systemic tumor control. Used for Non-small cell lung cancer (in combination with radiotherapy), Other solid tumors amenable to radiotherapy (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}